AVANT to Report Fourth Quarter and Year-End Fiscal 2007 Financial Results on February 27, 2008

Business Wire, Feb 20, 2008

- Conference Call to Follow -

NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will release its fourth quarter and fiscal 2007 financial results before U.S. financial markets open on Wednesday, February 27, 2008.

AVANT executives will host a conference call and live audio webcast at 11:00 am ET that same day. To access the live call, dial 888-713-4216 (within the United States) or 617-213-4868 (outside the United States). The passcode for participants is 90507438. A replay will be available approximately two hours after the live call. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode I.D. # is 96094569. The replay will also be broadcast via the company's website www.avantimmune.com approximately two hours after the live call.

About AVANT Immunotherapeutics, Inc.

AVANT Immunotherapeutics, Inc. is a Massachusetts-based NASDAQ-listed company discovering and developing innovative vaccines and therapeutics that harness the human immune system to prevent and treat disease. AVANT's innovative bacterial vector delivery technologies with unique manufacturing and preservation processes offer the potential for a new generation of vaccines. AVANT has three commercialized products, including Rotarix([R]) for the treatment of rotavirus and two human food safety vaccines for reducing salmonella infection in chickens and eggs. AVANT also has four product candidates in its development pipeline, an anti-inflammatory agent, TP10, and three candidates based on its oral, rapidly-protecting, single-dose and temperature-stable vaccine technology, including combination vaccines for travelers, the military and global health needs.